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eta2-Adrenergic
eceptor Gene Polymorphisms
ill the Important
ne Please Step Forward?*
artin C. Michel, MD,† Rainer Büscher, MD‡
msterdam, the Netherlands; and Essen, Germany
eta2-adrenergic receptors (B2ARs) contribute to the reg-
lation of many physiological functions in, for example,
lood vessels, the heart, airways, and the uterus. They also
re the molecular target of clinically important drugs,
articularly in the treatment of obstructive airway disease.
he human gene encoding the B2AR resides on chromo-
ome 5q31-32. However, at least 12 single nucleotide
olymorphisms (SNPs) in the coding and several more in
he promoter region have been identified (1). Many of these
re synonymous SNPs and/or have not been well character-
zed at the molecular level or in clinical association studies.
ost reported studies relate to the nonsynonymous poly-
orphisms arginine at position 16 replaced by glycine
Arg16Gly) and glutamine at position 27 replaced by
lutamic acid (Gln27Glu) and, more rarely, threonine at
osition 164 replaced by isoleucine (Thr164Ile). Even
hough polymorphisms in positions 16 and 27 may be
ssociated with altered treatment responses in some cases,
ssociation studies have not consistently implicated them
lone or as part of haplotypes in the pathophysiology of
ardiovascular or airway disease (1–3).
See page 1381
In this issue of the Journal, Piscione et al. (4) report that
he Thr164Ile SNP of the B2AR gene is associated with
oronary and peripheral artery disease. The Thr164Ile
olymorphism is infrequent in the general population of
arious ethnicities, typically being present in 4% in its
eterozygous form, and subjects homozygous for the iso-
eucine at position 164 (Ile164) genotype may not exist (1).
espite its limited prevalence, this SNP may be important
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Pharmacology and Pharmacotherapy, Academic Med-r
cal Center, University of Amsterdam, Amsterdam, the Netherlands; and the
Department of Pediatrics II, University of Duisburg-Essen, Essen, Germany.s it has consistently been shown in transfected cells (4–6)
r in native cells from genotyped subjects (7–9) that the
le164 variant is hypofunctional: that is, it produces smaller
ellular responses upon agonist stimulation. This hypore-
ponsiveness is not explained by altered expression levels but
ather is due to an intrinsically impaired signaling capacity
f the receptor variant. Accordingly, mice transgenic for the
le164 genotype exhibit smaller adenylyl cyclase, heart rate,
nd inotropic responses than those transgenic for threonine
t position 164 (Thr164) (10). Taken together, these data
onsistently establish the Ile164 variant of the B2AR as
ypofunctional.
To assess the clinical relevance of the Thr164Ile poly-
orphism, both disease association and drug response
tudies have been performed. Association studies have been
ampered by the low prevalence of the Thr164Ile polymor-
hism, which necessitates large patient groups to reach
obust conclusions. With regard to arterial hypertension,
le164 was associated with an increased risk for high blood
ressure in women (but not men) of 1 large (9,185 subjects)
anish population study (11), whereas no such association
etween genotype at this locus and blood pressure was
bserved in a smaller Italian population (775 hypertensive
atients) study (12), the lack of association in the latter
ossibly reflecting the limited statistical power of a smaller
opulation. Piscione et al. (4) now report that Ile164 is
uch more prevalent in a population of coronary artery
isease patients than in a control population (12% vs. 3%),
nd that within the patient group, Ile164 carriers exhibit a
ore severe pathology than those with Thr164 genotype.
imilarly, a group of patients with peripheral artery disease
lso exhibited a high prevalence of the Ile164 genotype (7%)
nd a more severe clinical phenotype than those with
hr164 (4). An early report on reduced survival in patients
ith congestive heart failure carrying 1 Ile164 allele (13) was
onfirmed in 1 (14) but not 2 other studies (15,16). Thus, in
ine with its hypofunctional properties in vitro, the Ile164
enotype is associated with clinical phenotypes reflecting a
educed vasodilation in most studies. Although B2AR can
ffect cardiac function in some settings (17), this role may be
nsufficient to yield consistent associations of the Thr164Ile
olymorphism with heart failure.
However, the Thr164Ile polymorphism may not only
ave pathophysiological but also therapeutic relevance.
hus, inotropy and heart rate responses to infusions of the
2AR agonist terbutaline were reduced in Ile164 carriers,
nd such findings were obtained in both healthy volunteers
18,19) and heart failure patients (14). Similarly, studies
sing the dorsal hand vein model reported impaired vaso-
ilation in healthy Ile164 carriers; this was based on a lower
gonist potency, whereas maximum dilation responses to
ocal agonist infusion were not affected (20,21). Reduced
2AR responses of Ile164 carriers were also reported for
ipolysis in isolated adipocytes (7), inhibition of histamine
elease from mast cells (9), and airway dilation and lympho-
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B2AR Polymorphisms October 21, 2008:1389–90yte cyclic adenosine monophosphate formation in cystic
brosis patients (8). Accordingly, the B2AR were proposed
o be disease-modifying genes in cystic fibrosis (22).
Taken together, the available data demonstrate that the
le164 variant of the B2AR is hypofunctional. This appears
o be associated with cardiovascular disease states in which
2AR are considered to be important. Moreover, it is
onsistently associated with reduced functional responses to
gonist stimulation in cardiovascular and other tissues. The
atter finding most likely is most important therapeutically
or airway disease but has only been studied to a limited
xtent in such patients. In a more general sense, these data
emonstrate that infrequent gene polymorphisms with ma-
or effects on the function of the associated protein may be
linically more relevant, at least in the afflicted subjects, than
ore frequent polymorphisms that affect gene function to a
ore limited extent.
eprint requests and correspondence: Prof. Martin C. Michel,
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